Modern Healthcare names Civica’s Heather Wall, Chief Commercial officer, as a Top 25 Women Leader.
Fast Company lists Civica as one of The World’s 50 Most Innovative Companies for manufacturing generic drugs at lower prices to combat shortages and rising healthcare costs.
Modern Healthcare names Martin VanTrieste, President and CEO of Civica Rx, as one of The 100 Most Influential People in Healthcare. “This recognition is a reflection of everything the Civica team has accomplished, and the great things we will do as a team in the future,” said VanTrieste. “I am honored to receive this recognition on behalf of the entire Civica team.”
The Medicine Maker selects Martin VanTrieste, Civica CEO, for its 2020 Power List and its 2019 Power List, naming him as one of the Champions of Change. “I am honored and deeply humbled to be recognized by The Medicine Maker. The credit goes to the entire Civica team for their hard work and dedication to serving patients.”-Martin VanTrieste, Civica CEO
MobiHealthNews, “digital health’s publication of record covering breaking news and contextualizing the trends for healthcare innovators,” recently cited Civica Rx as one of the few companies working to manufacture or distribute lower-cost drugs.
Modern Healthcare names Civica Rx’s Heather Wall to Women Leaders “10 to Watch” list. “We are incredibly fortunate to have Heather’s leadership, experience and passion for patients as we launch Civica Rx to reduce chronic drug shortages,” said Martin VanTrieste, CEO of Civica Rx
FierceHealthcare names Civica Rx as one of its 2019 “Fierce 15” companies, designating it as one of the most promising healthcare companies in the industry.
In reflecting on 2018, The Conversation, via the San Francisco Chronicle picks Civica Rx as one of its top three “solutions that chip away at big problems.”
Civica Rx comes in as #4 and #5 in Becker’s Hospital Review’s “top 10 supply chain stories of 2018.”
A Life Science Leader guest columnist provides a summary analysis of Civica Rx in his feature, “Assessing the impact of the Civica business model for pharma manufacturers.”
